Functional significance of varied quantitative and qualitative expression of HLA-A2.1 antigens in determining the susceptibility of cells to cytotoxic T lymphocytes

Human Immunology

Volumn 46, Issue 1, 1996, Pages 18-26

  Shieh, Dong Chen ^a   Gammon, Maureen C ^b   Zweerink, Hans J ^b   Kao, K J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; VIRUS ANTIGEN;

AMINO ACID SEQUENCE; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; INFLUENZA VIRUS; LYMPHOBLASTOID CELL; PRIORITY JOURNAL;

EID: 0029926914     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/0198-8859(96)00008-0     Document Type: Article

References (28)

1. Howard JC: Supply and transport of peptides presented by class I MHC molecules. Curr Opin Immunol 7:69, 1995.
2. Germain RN, Margulies DH: The biochemistry and cell biology of antigen processing and presentation. Annu Rev Immunol 11:403, 1993.
3. Schumacher TNM, De Bruijn MLH, Vernie LN, Kast WM, Melief CJM, Neefjes JJ, Ploegh HL: Peptide selection by MHC class I molecules. Nature 350:703, 1991.
4. Kao KJ, Scornik JC, McQueen CF: Evaluation of individual specificities of class I HLA on platelets by a newly developed monoclonal antibody. Hum Immunol 27:285, 1990.
5. Liebert M, Aster RH: Expression of HLA-B12 on platelets, on lymphocytes and in serum: a quantitative study. Tissue Antigens 9:199, 1977.
6. Kao KJ, Riley WJ: Genetic predetermination of quantitative expression of HLA antigens in platelets and mononuclear leukocytes. Hum Immunol 38:243, 1993.
7. Shieh DC, Kao KJ: Proportional amplification of individual HLA-A and -B antigens during upregulated expression of total class I HLA molecules. Hum Immunol 42:174, 1995.
8. Bakowski JF, Welsh RM: Interferon enhances the susceptibility of virus infected fibroblasts to cytotoxic T cells. J Exp Med 161:257, 1985.
9. Mishell BB, Shiiigi SM: Modification and use of antibodies to label cell surface antigens. In Mishell BB, Shiiigi SM (eds): Selected Methods in Cellular Immunology, San Francisco, W.H. Freeman, 1980.
10. Bednarek MA, Engl SA, Gammon MC, Lindquist JA, Porter G, Williamson AR, Zweerink HJ: Soluble HLA-A2.1 restricted peptides that are recognized by influenza virus specific cytotoxic T lymphocytes. J Immunol Methods 139:41, 1991.
11. Bender BS, Croghan T, Zhang L, Small PA: Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med 175:1143, 1992.
12. Steinle A, Reinhardt C, Nobner E, Uchanska-Ziegler B, Ziegler A, Schendel DJ: Microheterogeneity in HLA-B35 alleles influences peptide-dependent allorecognition by cytotoxic T cells but not binding of a peptide-restricted monoclonal antibody. Hum Immunol 38:261, 1993.
13. Holland LJ, Wangh LJ: Efficient recovery of functionally intact mRNA from agarose gels via transfer to an ion-exchange membrane. Nucleic Acids Res 11:3283, 1983.
14. Zeh III HJ, Leder GH, Lotze MT, Salter RD, Tector M, Stuber G, Modrow S, Storkus WJ: Flow-cytometric determination of peptide-class I complex formation: identification of p53 peptides that bind to HLA-A2. Hum Immunol, 39:79, 1994.
15. Shimojo N, Anderson RW, Mattson DH, Turner RV, Coligan JE, Biddison WE: The kinetics of peptide binding to HLA-A2 and the conformation of the peptide-A2 complex can be determined by amino acid side chains on the floor of the peptide binding groove. Int Immunol 2:193, 1990.
16. Domenech N, Ezquerra A, Castano R, Lopez de Castro JA: Structural analysis of HLA-A2.4 functional variant KNE: implication for the mapping of HLA-A2-specific T-cell epitopes. Immunogenetics 27:196, 1988.
17. Saper MA, Bjorkman PJ, Wiley DC: Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J Mol Biol 219:277, 1991.
18. Matsui M, Moots RJ, McMichael AJ, Frelinger JA: Significance of the six peptide-binding pockets of HLA-A2.1 in influenza A matrix peptide-specific cytotoxic T-lymphocyte reactivity. Hum Immunol 41:160, 1994.
19. Hogan KT, Shimojo N, Walk SF, Engelhard VH, Maloy WL, Coligan JE, Biddison WE: Mutations in the alpha2 helix of HLA-A2 affect presentation but do not inhibit binding of influenza virus matrix peptide. J Exp Med 168:725, 1988.
20. Ljunggren HG, Stam NJ, Ohlen C, Neefjes JJ, Hoglund P, Heemels MT, Bastin J, Schumacher TNM, Townsend A, Karre K, Ploegh HL: Empty MHC class I molecules come out in the cold. Nature 346:476, 1990.
21. Benjamin RJ, Madrigal JA, Parham P: Peptide binding to empty HLA-B27 molecules of viable human cells. Nature 351:74, 1991.
22. Luescher IF, Romero P, Cerottini JC, Maryanski JL: Specific binding of antigenic peptides to cell-associated MHC class I molecules. Nature 351:72, 1991.
23. 2-microglobulin. Proc Natl Acad Sci USA 89: 7767, 1992.
24. Kovascovics-Bankowski M, Rock KL: A phagosome-tocytosol pathway for exogenous antigen presented on MHC class I molecules. Science 267:243, 1995.
25. Fernandez-Vina MA, Falco M, Sun Y, Stastny P: DNA typing for HLA class I alleles: I. Subtypes of HLA-A2 and of A28. Hum Immunol 33:163, 1992.
26. Krausa P, Brywka III M, Savage D, Hui KM, Bunce M, Ngai JLF, Teo DLT, Ong YW, Barouch D, Allsop CEM, Hill AVS, McMichael AJ, Bodmer JG, Browning MJ: Genetic polymorphism within HLA-A02: significant allelic variation revealed in different populations. Tissue Antigens 45:223, 1995.
27. Shieh DC, Kao KJ: A combined approach for quantitation of each specific HLA-A or -B antigen expressed on cells. J Immunol Methods 184:169, 1995.
28. del Guercio M-F, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, Sette A: Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 154:685, 1995.